Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older

Journal of Medical Virology

Volumn 89, Issue 1, 2017, Pages 91-98

  Akuta, Norio ^a   Sezaki, Hitomi ^a   Suzuki, Fumitaka ^a   Kawamura, Yusuke ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Kobayashi, Mariko ^a   Saitoh, Satoshi ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

AFP; asunaprevir; daclatasvir; elderly; HCV; liver stiffness; NS3; NS5A; resistance associated variant

Indexed keywords

ALPHA FETOPROTEIN; ANTIVIRUS AGENT; ASUNAPREVIR PLUS DACLATASVIR; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; UNCLASSIFIED DRUG; VIRUS RNA; ASUNAPREVIR; BMS-790052; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HUMAN; INTENTION TO TREAT ANALYSIS; JAPANESE (PEOPLE); LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PREDICTION; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VERY ELDERLY; VIREMIA; ASIAN CONTINENTAL ANCESTRY GROUP; CLASSIFICATION; COMBINATION DRUG THERAPY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; LIVER; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 84973862211     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24592     Document Type: Article

References (21)

1. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2008. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. J Med Virol 80:1354–1362.
2. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, Calès P. Multicentric group from ANRS/HC/EP23 FIBROSTAR Studies. 2013. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 57:1182–1191.
3. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. 2012. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55:742–748.
4. Davis GL, Albright JE, Cook SF, Rosenberg DM. 2003. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9:331–338.
5. Gao M. 2013. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 3:514–520.
6. Kan H, Hiraga N, Imamura M, Hayes CN, Uchida T, Miyaki E, Tsuge M, Abe H, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. 2015. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice. Antivir Ther [Epub ahead of print].
7. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H. 2013. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 58:646–654.
8. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. 2014. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59:2083–2091.
9. ® M and XL probes according to the skin capsular distance. J Gastroenterol 51:496–505.
10. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366:216–224.
11. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, Levine S, Chaniewski S, Yu F, Barry D, Chen C, Lee MS, Mosure K, Sun LQ, Sinz M, Meanwell NA, Colonno RJ, Knipe J, Scola P. 2012. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 56:5387–5396.
12. McPhee F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, Yu ML, Ahn SH, Ishikawa H, Bhore R, Zhou N, Hernandez D, Mendez P, Kumada H. 2015. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv Ther 32:637–649.
13. Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Hayes CN, Chayama K. 2015. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res [Epub ahead of print].
14. Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Yamasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. 2016. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol [Epub ahead of print.
15. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. 2013. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 58:655–662.
16. Tadokoro K, Suzuki F, Kobayashi M, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. 2014. Rapid and high sensitive detection of Y93H amino acid substitution in HCV NS5A region using the PCR-Invader assay. Kanzo 55:720–722.
17. Tatsumi A, Maekawa S, Sato M, Komatsu N, Miura M, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Enomoto N. 2015. Liver stiffness measurement for risk assessment of hepatocellular carcinoma. Hepatol Res 45:523–532.
18. Taura N, Hamasaki K, Nakao K, Ichikawa T, Nishimura D, Goto T, Fukuta M, Kawashimo H, Miyaaki H, Fujimoto M, Kusumoto K, Motoyoshi Y, Shibata H, Inokuchi K, Eguchi K. 2006. Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: Long-term trends in Japan. Oncol Rep 16:837–843.
19. Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y. 2016. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol [Epub ahead of print].
20. Uchida Y, Kouyama J, Naiki K, Mochida S. 2014. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS ONE 9:e112647.
21. Yoshizawa H, Tanaka J, Miyakawa Y. 2006. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 49:7–17.